Karlsson F A, Dahlberg P A
Clin Endocrinol (Oxf). 1981 Jun;14(6):579-85. doi: 10.1111/j.1365-2265.1981.tb02968.x.
Thyroid-stimulating antibodies (TSAb) were studied in patients with Graves' disease using a method based on cAMP production in isolated human thyroid membranes. Stimulation was detected in forty-one (82%) of fifty patients with untreated Graves' disease. In these subjects, the TSAb levels were correlated with the thyroid hormone levels. Among twenty patients treated for 1-2 months with carbimazole, 16 (80%) had positive TSAb. During prolonged treatment TSAb gradually diminished and finally normalized. In fifteen patients, it was possible to compare TSAb levels after cessation of previous medical therapy with TSAb levels at relapse. In nine of these patients, an increase of the TSAb level within the normal range at the time of relapse was found, in four the titres were positive. The results indicate that positive TSAb titres are markers of active Graves' disease and suggest that in such patients antithyroid therapy should be continued. A normal TSAb titre after anti-thyroid therapy does not exclude the possibility of relapse.
采用基于分离的人甲状腺膜中环磷酸腺苷（cAMP）产生的方法，对格雷夫斯病患者的促甲状腺素抗体（TSAb）进行了研究。在50例未经治疗的格雷夫斯病患者中，41例（82%）检测到刺激作用。在这些受试者中，TSAb水平与甲状腺激素水平相关。在20例接受甲巯咪唑治疗1 - 2个月的患者中，16例（80%）TSAb呈阳性。在长期治疗过程中，TSAb逐渐降低，最终恢复正常。在15例患者中，能够比较先前停止药物治疗后TSAb水平与复发时的TSAb水平。在这些患者中，9例在复发时发现TSAb水平在正常范围内升高，4例滴度呈阳性。结果表明，TSAb阳性滴度是活动性格雷夫斯病的标志物，并提示此类患者应继续进行抗甲状腺治疗。抗甲状腺治疗后TSAb滴度正常并不能排除复发的可能性。
